Current Atherosclerosis Reports

, Volume 11, Issue 1, pp 64–66 | Cite as

A review of trials evaluating nonstatin lipid-lowering therapies

Article
  • 42 Downloads

Abstract

Recently reported clinical trials raise doubts on the effectiveness of nonstatin lipid-lowering therapies in reducing the residual risk of cardiovascular events after statin monotherapy. Addition of torcetrapib to statin therapy increased overall mortality in coronary patients despite a marked increase in high-density lipoprotein cholesterol. Combining ezetimibe with statin therapy neither further reduces carotid atherosclerosis nor slows aortic stenosis, and it has not been shown to be superior to statin monotherapy in reducing cardiovascular events. Clinical trials currently in progress will more clearly delineate the cardiovascular effects of adding either ezetimibe or extended-release niacin/laropiprant to statin therapy.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Barter PJ, Caulfield M, Eriksson M, et al.: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109–2122.PubMedCrossRefGoogle Scholar
  2. 2.
    Bots ML, Visseren FL, Evans GW, et al.: Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007, 370:153–160.PubMedCrossRefGoogle Scholar
  3. 3.
    Nissen SE, Tardif JC, Nicholls SJ, et al.: Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007, 356:1304–1316.PubMedCrossRefGoogle Scholar
  4. 4.
    Kastelein JJ, Akdim F, Stroes ES, et al.: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1431–1443.PubMedCrossRefGoogle Scholar
  5. 5.
    Smilde TJ, van Wissen S, Wollersheim H, et al.: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001, 357:577–581.PubMedCrossRefGoogle Scholar
  6. 6.
    Crouse JR 3rd, Raichlen JS, Riley WA, et al.: Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007, 297:1344–1353.PubMedCrossRefGoogle Scholar
  7. 7.
    Merck, Inc.: ACHIEVE Imaging Study Discontinued. Available at: http://www.merck.com/newsroom/press_releases/research_and_development/2008_0521. Accessed on August 4, 2008.
  8. 8.
    Merck, Inc.: Merck Receives Not Approvable Letter from FDA for MK-0524A (ER niacin/laropiprant). Available at: http://www.merck.com/newsroom/press_releases/research_and_development/2008_0428.html. Accessed on August 4, 2008.
  9. 9.
    Rossebo AB, Pedersen TR, Boman K, et al.: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008 (in press).Google Scholar
  10. 10.
    MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7–22.Google Scholar
  11. 11.
    Peto R, Emberson J, Landray M, et al.: Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008 (in press).Google Scholar
  12. 12.
    Brunzell JD, Davidson M, Furberg CD, et al.: Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008, 51:1512–1524.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2009

Authors and Affiliations

  1. 1.Atherosclerosis Research Unit, Division of Cardiology, Department of MedicineDavid Geffen School of Medicine at UCLALos AngelesUSA

Personalised recommendations